Cybin highlights recent topline results and outlines key upcoming milestones across its clinical development programs

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today outlined its recent positive phase 2 cyb003 topline results in mdd and near-term milestones across its clinical-stage deuterated psilocybin and ddmt programs in development for the treatment of multiple mental health con.
CYBN Ratings Summary
CYBN Quant Ranking